ArriVent BioPharma, Inc. Common Stock (AVBP) — Strategic Asset Allocation Index
ArriVent BioPharma, Inc. Common Stock (AVBP) has a Strategic Asset Allocation Index of 0.0% as of December 2025. Strategic assets (PP&E of $- plus long-term investments of $0.00) total $0.00, measured against net assets of $307.22 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
ArriVent BioPharma, Inc. Common Stock Strategic Asset Allocation Index (2023–2025)
This chart shows how ArriVent BioPharma, Inc. Common Stock's Strategic Asset Allocation Index has evolved across 3 annual periods from 2023 to 2025. As of December 2025, the index stands at 0.0%, representing strategic assets of $0.00 against net assets of $307.22 Million USD. Explore ArriVent BioPharma, Inc. Common Stock (AVBP) cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for ArriVent BioPharma, Inc. Common Stock (2023–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for ArriVent BioPharma, Inc. Common Stock from 2023 to 2025, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see ArriVent BioPharma, Inc. Common Stock (AVBP) market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 0.0% | $0.00 | $- | $0.00 | $307.22 Million | ▼ -18.5 pp |
| 2024 | 18.5% | $47.68 Million | $- | $47.68 Million | $257.65 Million | ▲ +18.5 pp |
| 2023 | 0.0% | $0.00 | $- | $0.00 | $151.30 Million | — |